Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Structures and people to govern Dementias Platform UK

Dementias Platform UK (DPUK) is a multi-million pound public-private partnership which launched in 2014. DPUK is directed by Professor John Gallacher (University of Oxford) and is supported by an executive team of ten other representatives from our academic and industry partners.

Governance structure


A steering group of 20 senior scientists, many of whom lead projects across the platform, influence the scientific direction of the project by making recommendations to the executive team.

The director and executive team, in turn, report to an MRC-appointed oversight board twice a year. The board oversee DPUK activity and advise on opportunities or changes for the project. Its members are UK and international experts in the field of dementia.

DPUK is supported by four international advisors, all experts in the field of dementia and neurodegenerative disease.

Funding to enable the platform’s work

Dementias Platform UK has received £53 million from the UK Medical Research Council. Each of our industry partners also makes a contribution – financial or in-kind – to enable the work of the platform.

 The amount of additional funding for dementia research that we have attracted can be seen in the table below.


£ m Funder and project Principal Investigator University Funding type
16 MRC-industry core funding John Gallacher Cardiff Core

MRC clinical research infrastructure:
Imaging network
Stem cells network
Informatics network

Paul Matthews 
Richard Wade-Martins
Simon Lovestone

Imperial College London, 


MRC: Imaging partnership

Karl Herholz Manchester Supported
1 MRC: Stem Cells partnership Siddharthan Chandran Edinburgh Supported

Alzheimer's Research UK (ARUK): Imaging

David Thomas University College London Supported
2 Stroke Association: Vascular Risk Joanna Wardlaw Edinburgh Supported
0.5 Janssen and Alzheimer's Research UK (ARUK): Synaptic Health James Rowe Cambridge Supported
60 Innovative Medicines Initiative (IMI): European Prevention of Alzheimer's Dementia Consortium (EPAD) Craig Ritchie Edinburgh Enabled
7 MRC National Institute for Health Research (NIHR): Deep and Frequent Phenotyping Simon Lovestone Oxford Enabled
3.4 Innovative Medicines Initiative (IMI): Real World Outcomes Across the Alzheimer's Disease Spectrum (ROADS) John Gallacher Oxford Enabled
1.1 MRC: UK7T partnership  James Rowe Cambridge Enabled
7 MRC clinical research infrastructure: UK7T James Rowe Cambridge Enabled
0.1 MRC: Korea Chi-Hun Kim Oxford Enabled
Research income generated: £83.4 m (157% of core funding)